Back to Screener

Adagene Inc. American Depositary Shares (ADAG)

Price$3.89

Favorite Metrics

Price vs S&P 500 (26W)94.84%
Price vs S&P 500 (4W)-0.13%
Market Capitalization$188.12M

All Metrics

Book Value / Share (Quarterly)$0.88
P/TBV (Annual)0.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-6.18%
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)105.91%
Net Profit Margin (TTM)-53.87%
EPS (TTM)$-0.30
10-Day Avg Trading Volume0.45M
EPS Excl Extra (TTM)$-0.30
Revenue Growth (5Y)61.42%
EPS (Annual)$-0.30
ROI (Annual)-30.35%
Net Profit Margin (5Y Avg)-6860.31%
Cash / Share (Quarterly)$1.26
Revenue Growth QoQ (YoY)7333.04%
ROA (Last FY)-22.50%
Revenue Growth TTM (YoY)7333.04%
EBITD / Share (TTM)$-0.35
ROE (5Y Avg)-53.98%
Operating Margin (TTM)-74.96%
Cash Flow / Share (Annual)$-0.26
P/B Ratio3.62x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)15.61x
Net Interest Coverage (TTM)-79.31x
ROA (TTM)-24.33%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)3.07x
Quick Ratio (Quarterly)3.06x
3-Month Avg Trading Volume0.20M
52-Week Price Return151.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.92
P/S Ratio (Annual)24.52x
Asset Turnover (Annual)0.10x
52-Week High$4.75
Operating Margin (5Y Avg)-7372.27%
EPS Excl Extra (Annual)$-0.30
CapEx CAGR (5Y)-55.15%
26-Week Price Return103.59%
Quick Ratio (Annual)3.06x
13-Week Price Return120.56%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)3.07x
Enterprise Value$119.715
Revenue / Share Growth (5Y)52.04%
Asset Turnover (TTM)0.10x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-233.44%
Cash / Share (Annual)$1.26
3-Month Return Std Dev122.08%
Net Income / Employee (TTM)$-0
ROE (Last FY)-33.93%
EPS Basic Excl Extra (Annual)$-0.30
Receivables Turnover (TTM)6.20x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$-0.30
Receivables Turnover (Annual)6.19x
ROI (TTM)-34.34%
P/S Ratio (TTM)24.52x
Pretax Margin (5Y Avg)-6858.29%
Revenue / Share (Annual)$0.13
Tangible BV / Share (Annual)$1.92
Price vs S&P 500 (52W)116.17%
Year-to-Date Return110.05%
5-Day Price Return3.39%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-33.48%
Net Profit Margin (Annual)-229.56%
Month-to-Date Return1.28%
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-279.48%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-43.23%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.30
P/TBV (Quarterly)0.76x
P/B Ratio (Annual)1.65x
Pretax Margin (TTM)-57.76%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)117.69%
Beta0.65x
Revenue / Share (TTM)$0.13
ROE (TTM)-39.21%
52-Week Low$1.30

Industry Peers — Pharmaceuticals(308)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ADAGAdagene Inc. American Depositary Shares
24.52x7333.04%$3.89
LLYEli Lilly & Co.
13.45x44.70%83.04%27.59%$919.90
JNJJohnson & Johnson
5.82x7.87%67.95%14.90%$230.69
ABBVABBVIE INC.
5.97x8.57%71.62%-2.88%$203.71
MRKMerck & Co., Inc.
4.51x1.31%78.55%21.23%$117.10
AZNAstraZeneca PLC
5.39x8.63%81.31%21.88%$200.69
NVSNovartis AG
4.87x8.91%75.82%15.26%$150.99
NVONovo-Nordisk A/S
3.74x6.43%80.98%20.66%$40.46
ABTAbbott Laboratories
3.71x6.59%56.50%8.20%$96.00
PFEPfizer Inc.
2.50x-1.64%75.81%-3.51%$27.52
BMYBristol-Myers Squibb Co.
2.52x-0.22%72.63%$59.13

About

Adagene is a clinical-stage biopharmaceutical company developing monoclonal antibody immunotherapies for cancer treatment. The company's proprietary platform generates therapeutic antibody candidates with enhanced functional epitopes and species cross-reactivity, enabling a differentiated pipeline of cancer immunotherapy programs.